<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50551">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448121</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 25000039812/2005-99</org_study_id>
    <secondary_id>11738</secondary_id>
    <nct_id>NCT02448121</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Stem Cell Transplantation for Hip Osteonecrosis in Sickle Cell Disease</brief_title>
  <official_title>Treatment for Hip Osteonecrosis With Autologous Mononuclear Cells Transplantation in People With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Bahia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universit√°rio Professor Edgard Santos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Bahia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow
      stem cells in sickle cell disease patients with hip osteonecrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate autologous bone marrow stem cells transplantation as a
      safe and potentially beneficial treatment for sickle cell disease patients with hip
      osteonecrosis.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Harris Hip Score of 10 points or more</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric pain intensity scale (0-10)</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression defined as progression to a fractural stage of osteonecrosis</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>60 months</time_frame>
    <description>Need for further surgery or hip replacement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression</measure>
    <time_frame>60 months</time_frame>
    <description>Radiological progression is defined according to the development of the Ficat- and Steinberg-staging system of osteonecrosis. It is based on radiological findings in X-Ray and MRI scans, respectively, and it is useful in predicting outcomes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Avascular Necrosis of Femur Head</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem Cell Graft Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Graft Group</intervention_name>
    <description>All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.</description>
    <arm_group_label>Stem Cell Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous bone marrow stem cell</intervention_name>
    <description>Bone marrow ficoll separated mononuclear autologous cells. Autologous bone marrow cells collection under sedation, then processed through a ficoll gradient.</description>
    <arm_group_label>Stem Cell Transplantation</arm_group_label>
    <other_name>Autologous bone marrow-derived mononuclear cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable sickle cell disease patients

          -  FICAT classification of osteonecrosis, inclusive of Stage II.

          -  Diagnosis will be based on X-Ray and magnetic resonance imaging (MRI).

          -  No infection in affected bones at the time of surgery.

          -  Patient competent to give informed consent.

          -  Scoring at least 20 points on the pain and daily life activities questionnaire.

        Exclusion Criteria:

          -  FICAT stage III or more

          -  Patients with a history of corticosteroids or on active therapy

          -  Bone infection at the limb affected by necrosis

          -  Recurrent painful crises,

          -  Immunosuppressive drug therapy,

          -  Pregnancy,

          -  Presence of neoplastic disease or any other clinical concurrent condition other than
             sickle cell disease that predisposed them to the development of osteonecrosis of the
             femoral head
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GIldasio Daltro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vitor Fortuna, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Meyer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Radovan Borojevic, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <reference>
    <citation>Hernigou P, Daltro G, Filippini P, Mukasa MM, Manicom O. Percutaneous implantation of autologous bone marrow osteoprogenitor cells as treatment of bone avascular necrosis related to sickle cell disease. Open Orthop J. 2008 Apr 25;2:62-5. doi: 10.2174/1874325000802010062.</citation>
    <PMID>19478932</PMID>
  </reference>
  <reference>
    <citation>Hernigou P, Daltro G, Flouzat-Lachaniette CH, Roussignol X, Poignard A. Septic arthritis in adults with sickle cell disease often is associated with osteomyelitis or osteonecrosis. Clin Orthop Relat Res. 2010 Jun;468(6):1676-81. doi: 10.1007/s11999-009-1149-3. Epub 2009 Nov 3.</citation>
    <PMID>19885711</PMID>
  </reference>
  <results_reference>
    <citation>Daltro GC, Fortuna V, de Souza ES, Salles MM, Carreira AC, Meyer R, Freire SM, Borojevic R. Efficacy of autologous stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: a five-year follow-up study. Stem Cell Res Ther. 2015 May 29;6:110. doi: 10.1186/s13287-015-0105-2.</citation>
    <PMID>26021713</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 30, 2015</lastchanged_date>
  <firstreceived_date>May 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Bahia</investigator_affiliation>
    <investigator_full_name>Vitor Fortuna</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Cell therapy</keyword>
  <keyword>Sickle cell disease</keyword>
  <keyword>Hip Osteonecrosis</keyword>
  <keyword>Autologous implantation</keyword>
  <keyword>Mesenchymal stromal cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
